Key terms

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest OCUL news

Apr 08 6:37am ET Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler Apr 08 6:30am ET Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO) Apr 07 6:15pm ET Buy Rating Affirmed: Paxtrava’s Promising Efficacy and Safety Profile in Glaucoma Treatment Apr 07 6:29am ET Ocular Therapeutix announces Phase 2 PAXTRAVA glaucoma data Mar 25 4:43pm ET Ocular Therapeutix files to sell 43.22M shares of common stock for holders Mar 13 6:16am ET Buy Rating Affirmed for Ocular Therapeutix on Robust Revenue Growth and Clinical Trial Prospects Mar 13 6:10am ET Ocular Therapeutix price target raised to $15 from $12 at H.C. Wainwright Mar 13 2:30am ET Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT) Mar 12 7:25am ET Ocular Therapeutix price target raised to $11 from $8 at TD Cowen Mar 12 6:18am ET Ocular Therapeutix price target raised to $24 from $12 at JMP Securities Mar 12 5:20am ET Buy Rating Affirmed for Ocular Therapeutix on Strong Financials and Promising Pipeline Developments Mar 12 12:35am ET Buy Rating Affirmed for Ocular Therapeutix on Strong Phase 3 Results and Strategic Focus Mar 11 7:35pm ET Balanced Outlook: Hold Rating on Ocular Therapeutix Amidst Trial Progress and Management Changes Mar 11 4:23pm ET Ocular Therapeutix reports Q4 EPS (35c), consensus (30c) Mar 11 2:04pm ET Ocular Therapeutix options imply 11.5% move in share price post-earnings Mar 11 8:05am ET Options Volatility and Implied Earnings Moves Today, March 11, 2024 Mar 04 2:04pm ET Ocular Therapeutix options imply 8.8% move in share price post-earnings Feb 26 7:35am ET Ocular Therapeutix price target raised to $15 from $10 at Piper Sandler Feb 25 11:37pm ET Ocular Therapeutix Poised for Growth with Strategic Leadership Hires and Strong Financial Position Feb 23 5:19am ET Strategic Leadership and Strong Financials Bolster Buy Rating for Ocular Therapeutix Feb 22 7:54am ET Ocular Therapeutix Raises $325M in Strategic Equity Financing Feb 22 7:52am ET Ocular Therapeutix reports inducement grants under Nasdaq listing rule Feb 22 7:49am ET Ocular Therapeutix announces board of directors, leadership changes Feb 22 7:46am ET Ocular Therapeutix sells 32.4M shares at $7.52 in private placement Feb 15 8:06am ET Ocular Therapeutix appoints Meyers to Chief Commercial Officer Feb 13 9:35am ET Buy Recommendation for Ocular Therapeutix on Positive SOL Trial Amendments and Strong Pipeline Positioning Feb 12 11:09am ET Biotech Alert: Searches spiking for these stocks today Feb 09 9:41am ET PayPal downgraded, United Airlines upgraded: Wall Street’s top analyst calls Feb 09 7:58am ET Piper Sandler Sticks to Its Buy Rating for Ocular Therapeutix (OCUL) Feb 09 6:14am ET Ocular Therapeutix initiated with a Buy, $15 target at BofA Feb 09 6:03am ET Ocular Therapeutix initiated with a Buy at BofA

No recent news articles are available for OCUL

No recent press releases are available for OCUL

OCUL Financials

1-year income & revenue

Key terms

OCUL Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

OCUL Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms